Jacobio Pharmaceuticals Group Co., Ltd. (1167) AI Stock Analysis

• Market Cap: HK$3.74B
• Dividend Yield: N/A
• Average Volume (3M): 5.36M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 139.04%
• EPS Growth: 57.13%
• Country: HK
• Employees: 257
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 791,755,070
• 10 Day Avg. Volume: 2,730,880
• 30 Day Avg. Volume: 5,360,118
• PEG Ratio: -0.33
• Price to Book (P/B): 2.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$5.30
• Price Target Upside: 12.29% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ―

Jacobio Pharmaceuticals Group Co., Ltd. is experiencing financial instability characterized by consistent net losses and operational inefficiencies. However, a strong cash position and recent positive technical indicators provide some optimism. The high beta indicates potential volatility, and the lack of profitability reflected in the negative P/E ratio remains a concern. Overall, improvement in financial performance and profitability would be key to raising the stock's attractiveness.

Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model

Company Description

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.

How the Company Makes Money

Jacobio Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company invests heavily in research and development to bring its proprietary therapies to market. Revenue streams include milestone payments and royalties from licensing agreements with other pharmaceutical companies, as well as potential sales of its own marketed drugs once they receive regulatory approval. Jacobio may also engage in strategic partnerships and collaborations to co-develop and commercialize products, which can provide additional funding and resources to accelerate its R&D efforts.

Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview

Summary

Jacobio Pharmaceuticals Group Co., Ltd. faces significant challenges with consistent net losses and operational inefficiencies impacting profitability and cash flow. While a strong cash position provides some liquidity buffer, declining revenue, negative equity history, and poor cash flow metrics highlight financial instability. Improvement in operational efficiency and revenue growth is necessary to enhance financial health.

Income Statement

The company has experienced significant volatility in revenue, with a notable decline from 2020 to 2023 and some recovery in 2024. Gross profit margin is positive in the latest year, but net profit margin remains negative due to high operating expenses and consistent net losses. The EBIT and EBITDA margins are also unfavorable, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong cash position relative to debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the equity ratio has decreased over time, and the company has reported negative stockholders' equity in previous years, indicating financial instability. The debt-to-equity ratio is manageable, but the declining equity base is a concern.

Cash Flow

The company has struggled with negative operating cash flow and free cash flow over the years, reflecting operational inefficiencies. The lack of free cash flow growth and negative cash flow from operations are significant concerns, although the company maintains a strong cash reserve.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	155.71M	63.52M	95.75M	152.81M	486.29M
Gross Profit	155.71M	3.20M	12.63M	12.83M	442.17M
EBITDA	-192.36M	-325.73M	-355.80M	-289.83M	-1.50B
Net Income	-155.71M	-359.12M	-374.88M	-292.29M	-3.21B
Balance Sheet
Total Assets	1.36B	1.46B	1.57B	1.72B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.17B	1.15B	1.28B	1.53B	1.63B
Total Debt	152.08M	209.91M	147.79M	6.81M	10.65M
Total Liabilities	435.99M	387.11M	292.12M	84.75M	81.15M
Stockholders Equity	923.18M	1.07B	1.28B	1.64B	1.79B
Cash Flow
Free Cash Flow	-86.21M	-402.86M	-308.92M	-158.63M	67.87M
Operating Cash Flow	-74.12M	-364.20M	-292.42M	-147.49M	78.83M
Investing Cash Flow	0.00	-48.00M	-686.32M	161.67M	-215.56M
Financing Cash Flow	21.28M	246.28M	-9.85M	109.06M	1.28B

Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Positive. The current price of 4.72 is below the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.71, and above the 200-day MA of 2.72, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 49.24 is Neutral, neither overbought nor oversold. The STOCH value of 68.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1167.

Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	59 Neutral	HK$1.43B	35.78	4.92%	―	38.48%	―
2616	55 Neutral	HK$7.19B	―	-22.23%	―	-14.17%	76.00%
1873	52 Neutral	HK$3.17B	17.77	4.47%	―	-9.75%	―
Sector *	52 Neutral	$7.52B	0.25	-63.76%	2.30%	16.15%	0.89%
1167	50 Neutral	HK$3.74B	―	-15.59%	―	139.04%	57.13%
3681	50 Neutral	HK$2.40B	―	-75.64%	―	42.21%	29.52%
2179	46 Neutral	HK$3.70B	―	-69.97%	―	―	3.30%

Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events

Jacobio Pharmaceuticals Announces Changes in Concert Party Interests

Jacobio Pharmaceuticals Group Co., Ltd. announced changes in the interests of parties acting in concert, with voting rights decreasing from approximately 26.67% to 25.21% due to the departure of certain individuals. Despite this change, the company remains committed to its business strategy and long-term development plan, with the largest shareholder group maintaining its position. Departed individuals have expressed confidence in the company’s long-term value by voluntarily agreeing to a one-year lock-up on their shares, indicating stability and trust in the company’s future.

Jacobio Pharmaceuticals Advances Cancer Drug Pipeline with Strategic Licensing and Trials

Jacobio Pharmaceuticals has announced significant progress in its drug development pipeline, including the submission of a New Drug Application for glecirasib for second-line NSCLC in China and the initiation of pivotal trials for other cancer types. The company has licensed the Greater China rights of glecirasib and sitneprotafib to Allist, securing a deal worth RMB900 million plus royalties, and launched first-in-human trials in the U.S. and China, reinforcing its position as a leader in the global R&D biotech space.

Jacobio Pharmaceuticals Announces Board Composition and Roles

Jacobio Pharmaceuticals Group Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This update includes the appointment of executive, non-executive, and independent non-executive directors, as well as their assignments to various board committees, which may influence the company’s governance and strategic direction.